Pavel Yuryevich Mylnikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pavel Yuryevich Mylnikov has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey Vladimirovich Shchulkin
Рязанский государственный медицинский университет им. академика И. П. Павлова
33 shared publications - Elena Nikolaevna Yakusheva
Рязанский государственный медицинский университет имени академика И. П. Павлова
26 shared publications - Ivan Vladimirovich Chernykh
Ryazan State Medical University, Ryazan, Russian Federation
13 shared publications - Yu. Tranova
Ryazan State Medical University
7 shared publications - Yuliya Vladimirovna Abalenikhina
Ryazan State Medical University, Ryazan, Russia
7 shared publications - Sergey V. Seleznev
Рязанский государственный медицинский университет им. академика И. П. Павлова
6 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 95-105
Development and validation of a method for the quantitative determination of succinate in rat blood plasma by HPLC-MS/MS
Relevance. Succinate is a central metabolite of the Krebs cycle and also a regulator of numerous processes via the specific succinate receptor SUCNR1. Succinate is an important component of several pharmacological preparations. However, its pharmacokinetics following the administration of these substances remain poorly understood. A sensitive analytical method is required to perform such studies. Objective. To develop and validate a method for the quantitative determination of succinate in rat blood plasma. Methods. The analysis was performed using HPLC-MS/MS — an Ultimate 3000 TSQ Fortis system and a UCT Selectra C18 column (4.6 mm × 100 mm, 3 µm, 100 Å). The separation temperature was 35 °C, and the flow rate was 0.5 mL/min. A gradient elution mode was used with a mixture of 0.1 % aqueous formic acid and 0.1 % formic acid in methanol. The injection volume was 5 µL. For sample preparation, methanol containing chloramphenicol at a concentration of 10 ng/mL as an internal standard was used. A model matrix was used during validation. For succinate detection, the following mass transitions were used in negative ionization mode: 117 m/z → 98.7 m/z, 117 m/z → 73.1 m/z. Results. The method demonstrated selectivity, sensitivity, accuracy, precision, and linearity in the concentration range of 200–20,000 ng/mL. No carryover or matrix effect was observed. The recovery rate was over 96 %. Succinate was stable under the employed storage conditions. Conclusion. A method for the quantitative determination of succinate in rat blood plasma has been developed and validated. This method can be used to analyze endogenous succinate concentrations and the pharmacokinetics of succinate following the administration of succinate-containing drugs.
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 95-105
Open AccessDevelopment and validation of a method for the quantitative determination of succinate in rat blood plasma by HPLC-MS/MS
Relevance. Succinate is a central metabolite of the Krebs cycle and also a regulator of numerous processes via the specific succinate receptor SUCNR1. Succinate is an important component of several pharmacological preparations. However, its pharmacokinetics following the administration of these substances remain poorly understood. A sensitive analytical method is required to perform such studies. Objective. To develop and validate a method for the quantitative determination of succinate in rat blood plasma. Methods. The analysis was performed using HPLC-MS/MS — an Ultimate 3000 TSQ Fortis system and a UCT Selectra C18 column (4.6 mm × 100 mm, 3 µm, 100 Å). The separation temperature was 35 °C, and the flow rate was 0.5 mL/min. A gradient elution mode was used with a mixture of 0.1 % aqueous formic acid and 0.1 % formic acid in methanol. The injection volume was 5 µL. For sample preparation, methanol containing chloramphenicol at a concentration of 10 ng/mL as an internal standard was used. A model matrix was used during validation. For succinate detection, the following mass transitions were used in negative ionization mode: 117 m/z → 98.7 m/z, 117 m/z → 73.1 m/z. Results. The method demonstrated selectivity, sensitivity, accuracy, precision, and linearity in the concentration range of 200–20,000 ng/mL. No carryover or matrix effect was observed. The recovery rate was over 96 %. Succinate was stable under the employed storage conditions. Conclusion. A method for the quantitative determination of succinate in rat blood plasma has been developed and validated. This method can be used to analyze endogenous succinate concentrations and the pharmacokinetics of succinate following the administration of succinate-containing drugs.
- Open Access
- 9 April 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (1) , 107-116
Antihypertensive drugs pharmacokinetics evaluation for predicting blood pressure control in comorbid hypertensive patients
Background . Evaluation of the effect of antihypertensive drug (AHD) concentrations on blood pressure (BP) in comorbid patients may help optimize the treatment of arterial hypertension (HTN). The aim of the study was the effect of the AHD (lisinopril, amlodipine, indapamide) concentration assessment on BP in comorbid HTN patients to optimize antihypertensive therapy. Design and methods. A prospective clinical controlled study was performed. In comorbid patients with essential HTN and regular use of lisinopril, amlodipine and indapamide, fasting blood samples were taken to determine the concentration of AHD using high-performance liquid chromatography with tandem mass spectrometry. Comorbidity was assessed by Charlson index. Results . In this study 183 patients were enrolled, the mean age was 63,4 ± 11,1 years, 42,6 % were men. The analysis of covariance (ANCOVA) showed that a decrease in the concentration of each of the studied AHD below the therapeutic range (TR) did not affect the magnitude of daytime and nighttime systolic and diastolic blood pressure (SBP and DBP). At the same time, blood pressure in patients whose concentrations of the two drugs amlodipine and indapamide were recorded below TR, the levels of daytime DBP, nighttime SBP and DBP were statistically significantly (p < 0,05) higher than those in patients with concentrations of all AHD within TR. In one patient concentrations of all three drugs were below TR, and SBP day level was 164 mmHg, DBP day — 102 mmHg, SBP night — 157 mmHg, DBP night — 97 mmHg. Conclusion . Our results indicate that the decrease in the concentration below TR of at least two antihypertensive drugs (amlodipine and indapamide in our study) affects the level of BP. Analysis of the concentration of AHD in HTN patients may be useful and can increase the treatment effectiveness.
- 9 April 2026
- Published by Arterialnaya Gipertenziya in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
- Vol. 32 (1) , 107-116
Open AccessAntihypertensive drugs pharmacokinetics evaluation for predicting blood pressure control in comorbid hypertensive patients
Background . Evaluation of the effect of antihypertensive drug (AHD) concentrations on blood pressure (BP) in comorbid patients may help optimize the treatment of arterial hypertension (HTN). The aim of the study was the effect of the AHD (lisinopril, amlodipine, indapamide) concentration assessment on BP in comorbid HTN patients to optimize antihypertensive therapy. Design and methods. A prospective clinical controlled study was performed. In comorbid patients with essential HTN and regular use of lisinopril, amlodipine and indapamide, fasting blood samples were taken to determine the concentration of AHD using high-performance liquid chromatography with tandem mass spectrometry. Comorbidity was assessed by Charlson index. Results . In this study 183 patients were enrolled, the mean age was 63,4 ± 11,1 years, 42,6 % were men. The analysis of covariance (ANCOVA) showed that a decrease in the concentration of each of the studied AHD below the therapeutic range (TR) did not affect the magnitude of daytime and nighttime systolic and diastolic blood pressure (SBP and DBP). At the same time, blood pressure in patients whose concentrations of the two drugs amlodipine and indapamide were recorded below TR, the levels of daytime DBP, nighttime SBP and DBP were statistically significantly (p < 0,05) higher than those in patients with concentrations of all AHD within TR. In one patient concentrations of all three drugs were below TR, and SBP day level was 164 mmHg, DBP day — 102 mmHg, SBP night — 157 mmHg, DBP night — 97 mmHg. Conclusion . Our results indicate that the decrease in the concentration below TR of at least two antihypertensive drugs (amlodipine and indapamide in our study) affects the level of BP. Analysis of the concentration of AHD in HTN patients may be useful and can increase the treatment effectiveness.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Experimental substantiation of in vivo methods for evaluating substrates and modulators of BCRP transporter protein activity
Relevance. BCRP (Human Breast Cancer Resistance Protein) (ABCG2, MXR; ABCP) is an efflux ATP-dependent transporter protein that plays a crucial role in the pharmacokinetics of a wide range of drugs. To enhance therapeutic safety and predict potential pharmacokinetic drug-drug interactions, international regulatory bodies recommend testing medicinal substances for their affiliation with substrates and inhibitors of BCRP. Preclinical studies are primarily conducted using cell lines that overexpress BCRP in vitro. Objective. The aim was to develop and experimentally validate a methodology for assessing medicinal substances as substrates or modulators of BCRP activity in vivo. Materials and methods . Six sexually mature male rabbits of the Soviet Chinchilla breed, weighing between 3000 g and 4000 g, were used in this study. Sulphasalazine was chosen as the classical substrate for BCRP and was administered intragastrically at a dose of 125 mg/kg. Pharmacokinetic evaluation involved blood sampling from ear veins at time points 0.25 h; 0.5 h; 1 h; 1.5 h; 2 h; 3 h; 5 h; 8 h; 12 h; and 24 h post-administration. Quercetin, known as a potent inhibitor of the transporter, was also administered either as a single dose (100 mg/kg) or chronically (25 mg/kg daily for seven days). After both acute and chronic quercetin administration, sulphasalazine was reintroduced, and its pharmacokinetics were assessed again. Plasma concentrations of sulphasalazine were analyzed by HPLC-MS/MS. Model-independent methods were employed to calculate pharmacokinetic parameters. Differences among groups were evaluated via analysis of variance, assuming a log-normal distribution of data. Results . With a single administration of the BCRP inhibitor quercetin to rabbits, of all the tested pharmacokinetic parameters of sulfasalazine, only C max significantly increased, while the remaining parameters (AUC 0-t ; AUC 0-∞ and T1/2) did not significantly change (p > 0.05). With the course administration of the BCRP inhibitor, a significant increase in Cmax values was observed by 3.1 times, AUC 0-t and AUC 0-∞ by 2.81 times (p = 0.0048**) and 2.49 times (p = 0.0192*), respectively, of the sulfasalazine transporter substrate, indicating a decrease in BCRP activity. In this case, inhibition depends on the duration of quercetin administration, which is confirmed by a significant difference in pharmacokinetic parameters between a series of single and course injections of the substance (p < 0.05). Conclusion . An original method has been developed and experimentally validated for testing medicinal compounds as substrates or modulators of BCRP activity in vivo using male Soviet Chinchilla rabbits as test subjects, with sulphasalazine (125 mg/kg) serving as the transporter substrate and quercetin (administered either as a single dose of 100 mg/kg or as a course of 25 mg/kg/day for seven days) as the inhibitor.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Experimental substantiation of in vivo methods for evaluating substrates and modulators of BCRP transporter protein activity
Relevance. BCRP (Human Breast Cancer Resistance Protein) (ABCG2, MXR; ABCP) is an efflux ATP-dependent transporter protein that plays a crucial role in the pharmacokinetics of a wide range of drugs. To enhance therapeutic safety and predict potential pharmacokinetic drug-drug interactions, international regulatory bodies recommend testing medicinal substances for their affiliation with substrates and inhibitors of BCRP. Preclinical studies are primarily conducted using cell lines that overexpress BCRP in vitro. Objective. The aim was to develop and experimentally validate a methodology for assessing medicinal substances as substrates or modulators of BCRP activity in vivo. Materials and methods . Six sexually mature male rabbits of the Soviet Chinchilla breed, weighing between 3000 g and 4000 g, were used in this study. Sulphasalazine was chosen as the classical substrate for BCRP and was administered intragastrically at a dose of 125 mg/kg. Pharmacokinetic evaluation involved blood sampling from ear veins at time points 0.25 h; 0.5 h; 1 h; 1.5 h; 2 h; 3 h; 5 h; 8 h; 12 h; and 24 h post-administration. Quercetin, known as a potent inhibitor of the transporter, was also administered either as a single dose (100 mg/kg) or chronically (25 mg/kg daily for seven days). After both acute and chronic quercetin administration, sulphasalazine was reintroduced, and its pharmacokinetics were assessed again. Plasma concentrations of sulphasalazine were analyzed by HPLC-MS/MS. Model-independent methods were employed to calculate pharmacokinetic parameters. Differences among groups were evaluated via analysis of variance, assuming a log-normal distribution of data. Results . With a single administration of the BCRP inhibitor quercetin to rabbits, of all the tested pharmacokinetic parameters of sulfasalazine, only C max significantly increased, while the remaining parameters (AUC 0-t ; AUC 0-∞ and T1/2) did not significantly change (p > 0.05). With the course administration of the BCRP inhibitor, a significant increase in Cmax values was observed by 3.1 times, AUC 0-t and AUC 0-∞ by 2.81 times (p = 0.0048**) and 2.49 times (p = 0.0192*), respectively, of the sulfasalazine transporter substrate, indicating a decrease in BCRP activity. In this case, inhibition depends on the duration of quercetin administration, which is confirmed by a significant difference in pharmacokinetic parameters between a series of single and course injections of the substance (p < 0.05). Conclusion . An original method has been developed and experimentally validated for testing medicinal compounds as substrates or modulators of BCRP activity in vivo using male Soviet Chinchilla rabbits as test subjects, with sulphasalazine (125 mg/kg) serving as the transporter substrate and quercetin (administered either as a single dose of 100 mg/kg or as a course of 25 mg/kg/day for seven days) as the inhibitor.
- Open Access
- 22 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (6) , 552-562
A comparative study of the therapeutic equivalence (efficacy, safety, and tolerability) and pharmacokinetics of brand-name and generic rivaroxaban in patients with non-valvular atrial fibrillation
Aim. To study the therapeutic equivalence (efficacy, safety, and tolerability) and pharmacokinetics of the brand-name and generic rivaroxaban 20 mg in patients with non-valvular atrial fibrillation and a high risk of thromboembolic complications. Material and methods. This open-label, randomized, crossover comparative study of two 20 mg rivaroxaban tablet formulations registered in Russia, Riqulatron (Gedeon Richter OJSC, Hungary) and Xarelto® (Bayer Pharma AG, Germany), included 30 patients (16 men), with a median age of 66 years and a СHA2DS2-VASc score of 3.0 (2.3-4.0). The clinical part consisted of: a screening period (1-7 days before randomization), two 42-day rivaroxaban treatment periods with a visit on day 14±1 of each, an interim visit for drug switching, and a final visit. Patients completed a drug intake diary and an adherence questionnaire. Quantitative determination of rivaroxaban concentration in patient plasma was performed using high-performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS). Data were processed using StatSoft Statistica 13.0 (USA). Results. Data are presented for 29 patients. The steady-state trough and peak concentrations were 22.29 (3.78-101.76) ng/ml and 197.04 (118.00-376.78) ng/ml for the generic, and 20.55 (5.02-82.29) ng/ml and 179.38 (102.80-335.71) ng/ml for the brand-name drug, respectively. The 90% confidence intervals for the ratios of trough and peak concentrations were 0.93-1.25 and 0.99-1.21, respectively. Mean laboratory values for patients, regardless of the treatment sequence, were within reference ranges except for peak prothrombin time. Rivaroxaban concentration was a significant predictor of prothrombin time (pConclusion. The comparative study of the two rivaroxaban formulations demonstrated similar efficacy, safety, tolerability, and pharmacokinetics for Riqulatron (Gedeon Richter OJSC, Hungary) and Xarelto® (Bayer Pharma AG, Germany) at a 20 mg dose in patients with non-valvular atrial fibrillation.
- 22 January 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (6) , 552-562
Open AccessA comparative study of the therapeutic equivalence (efficacy, safety, and tolerability) and pharmacokinetics of brand-name and generic rivaroxaban in patients with non-valvular atrial fibrillation
Aim. To study the therapeutic equivalence (efficacy, safety, and tolerability) and pharmacokinetics of the brand-name and generic rivaroxaban 20 mg in patients with non-valvular atrial fibrillation and a high risk of thromboembolic complications. Material and methods. This open-label, randomized, crossover comparative study of two 20 mg rivaroxaban tablet formulations registered in Russia, Riqulatron (Gedeon Richter OJSC, Hungary) and Xarelto® (Bayer Pharma AG, Germany), included 30 patients (16 men), with a median age of 66 years and a СHA2DS2-VASc score of 3.0 (2.3-4.0). The clinical part consisted of: a screening period (1-7 days before randomization), two 42-day rivaroxaban treatment periods with a visit on day 14±1 of each, an interim visit for drug switching, and a final visit. Patients completed a drug intake diary and an adherence questionnaire. Quantitative determination of rivaroxaban concentration in patient plasma was performed using high-performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS). Data were processed using StatSoft Statistica 13.0 (USA). Results. Data are presented for 29 patients. The steady-state trough and peak concentrations were 22.29 (3.78-101.76) ng/ml and 197.04 (118.00-376.78) ng/ml for the generic, and 20.55 (5.02-82.29) ng/ml and 179.38 (102.80-335.71) ng/ml for the brand-name drug, respectively. The 90% confidence intervals for the ratios of trough and peak concentrations were 0.93-1.25 and 0.99-1.21, respectively. Mean laboratory values for patients, regardless of the treatment sequence, were within reference ranges except for peak prothrombin time. Rivaroxaban concentration was a significant predictor of prothrombin time (pConclusion. The comparative study of the two rivaroxaban formulations demonstrated similar efficacy, safety, tolerability, and pharmacokinetics for Riqulatron (Gedeon Richter OJSC, Hungary) and Xarelto® (Bayer Pharma AG, Germany) at a 20 mg dose in patients with non-valvular atrial fibrillation.
- 30 December 2025
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 13 (4)
Transfected Cell Lines as a Tool for Studying the Functioning of SLC Transporters in Pharmacology
INTRODUCTION: Transporter proteins play a key role in cellular transport of bioactive substances and drugs, regulating their influx (SLC transporters) and efflux (ABC transporters). Of particular interest are OATP1B1 and OATP1B3, members of the SLC transporter family, expressed in hepatocytes and responsible for transport of endogenous compounds and xenobiotics. Their impaired function due to genetic polymorphisms or drug interactions can lead to changes in the pharmacokinetics, toxicity and decreased therapeutic effectiveness. However, investigation of these transporters is impeded by the absence of optimal cell models reproducing their activity in vivo. Primary hepatocytes, despite their physiological relevance, have limited viability in culture, and standard cell lines (e.g., HepG2) exhibit low OATP expression. Therefore, transfected cell lines such as HEK293-OATP1B1/B3 are becoming a critical tool for research, despite the need for further validation and optimization of culture conditions. AIM: To carry out the comparative analysis of cell lines expressing OATP1B1/B3 and evaluate the role of transfected cells. MATERIALS AND METHODS: The article presents a literature review of PubMed, Medline, Springer, eLibrary databases, as well as relevant scientific articles retrieved using Google Scholar. The obtained relevant information is consolidated, structured and analyzed to examine the role of transfected cellular models expressing OATP1B1/B3. CONCLUSION: Literature data demonstrate that the use of transfected cell lines enables the separate study of transport activity, standardization of experiments and high-throughput screening of substrates and inhibitors. Transfected cells remain indispensable for preclinical studies facilitating the development of personalized medicine and creation of safe medical drugs.
- 30 December 2025
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 13 (4)
Transfected Cell Lines as a Tool for Studying the Functioning of SLC Transporters in Pharmacology
INTRODUCTION: Transporter proteins play a key role in cellular transport of bioactive substances and drugs, regulating their influx (SLC transporters) and efflux (ABC transporters). Of particular interest are OATP1B1 and OATP1B3, members of the SLC transporter family, expressed in hepatocytes and responsible for transport of endogenous compounds and xenobiotics. Their impaired function due to genetic polymorphisms or drug interactions can lead to changes in the pharmacokinetics, toxicity and decreased therapeutic effectiveness. However, investigation of these transporters is impeded by the absence of optimal cell models reproducing their activity in vivo. Primary hepatocytes, despite their physiological relevance, have limited viability in culture, and standard cell lines (e.g., HepG2) exhibit low OATP expression. Therefore, transfected cell lines such as HEK293-OATP1B1/B3 are becoming a critical tool for research, despite the need for further validation and optimization of culture conditions. AIM: To carry out the comparative analysis of cell lines expressing OATP1B1/B3 and evaluate the role of transfected cells. MATERIALS AND METHODS: The article presents a literature review of PubMed, Medline, Springer, eLibrary databases, as well as relevant scientific articles retrieved using Google Scholar. The obtained relevant information is consolidated, structured and analyzed to examine the role of transfected cellular models expressing OATP1B1/B3. CONCLUSION: Literature data demonstrate that the use of transfected cell lines enables the separate study of transport activity, standardization of experiments and high-throughput screening of substrates and inhibitors. Transfected cells remain indispensable for preclinical studies facilitating the development of personalized medicine and creation of safe medical drugs.
- Open Access
- 30 December 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (4) , 559-568
Non-achievement of therapeutic range of antihypertensive drug concentration in a triple combination as a cause of ineffective control of primary arterial hypertension: ambiguous results of a cross-sectional clinical trial in routine clinical practice
INTRODUCTION: High blood pressure (BP) is one most important risk factor for coronary heart disease, stroke, chronic kidney disease, and dementia. Despite a wide range of pharmacological and non-pharmacological treatments, BP control can be achieved in less than 50% of cases, therefore, the development of new methods to improve the effectiveness of arterial hypertension (AH) treatment is urgent. One possible approach is monitoring antihypertensive drug (AHD) for their correspondence to the therapeutic range (TR). AIM: To analyze the effect of serum concentrations of lisinopril, indapamide and amlodipine on blood pressure parameters in patients with stage III essential hypertension taking these drugs in a triple combination. METHODS: A cross-sectional clinical study included 147 patients with stage III essential hypertension who were simultaneously receiving the three studied AHDs (lisinopril, amlodipine, indapamide); mean age (63.7±11.0) years; 44% were men; 54% of patients had uncontrolled hypertension. Using high-performance liquid chromatography with tandem mass spectrometry (Ultimate 3000 chromatograph and TSQ Fortis mass spectrometer (ThermoFisher, USA)) the concentrations of AHDs in blood serum were analyzed: steady-state concentration (C0h) and 2 hours after administration of AHDs (C2h). Using univariate and then multivariate regression analysis, the existence of a relationship between the mean level of daytime and nighttime blood pressure, pharmacokinetic parameters (C0h, C2h, achievement of TR) and general clinical criteria (age, gender, body weight, creatinine clearance) was determined. RESULTS: The proportion of patients with C0h below TR was: 8.2% for lisinopril, 27.9% for amlodipine, 69.4% for indapamide, 8.8% for simultaneous indapamide and amlodipine, and 0.7% for the three simultaneous AHDs. The proportion of patients with non-achievement of the target BP level was the following: with C0h of lisinopril within the TR (n=135) — 56.0%, with C0h of lisinopril below the TR (n=12) — 33.0%, with C0h of amlodipine within the TR (n=106) — 57.0%, with C0h of amlodipine below the TR (n=41) — 49.0%, with C0h of indapamide within the TR (n=45) — 44.0%, with C0h of indapamide below the TR (n=102) — 59.0%, with C0h of indapamide and amlodipine simultaneously below the TR (n=13) — 85.0%, with C0h of the three drugs simultaneously below the TR (n=1) — 1 out of 1. According to the results of multiple regression analysis, a significant factor influencing the level of daytime SBP was age, daytime DBP — age and non-achievement of the TR of amlodipine and indapamide C0h; of nighttime SBP — body weight, of nighttime DBP — age and non-achievement of the TR of amlodipine and indapamide C0h. CONCLUSION: A high prevalence of subtherapeutic serum concentrations of indapamide and amlodipine has been recorded. Non-achievement of the TR level of both amlodipine and indapamide is associated with higher diastolic blood pressure with no significant effect on systolic blood pressure. The problem of poor hypertension control cannot be explained solely by serum antihypertensive drug concentrations — no convincing, unambiguous correlation has been established.
- 30 December 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (4) , 559-568
Open AccessNon-achievement of therapeutic range of antihypertensive drug concentration in a triple combination as a cause of ineffective control of primary arterial hypertension: ambiguous results of a cross-sectional clinical trial in routine clinical practice
INTRODUCTION: High blood pressure (BP) is one most important risk factor for coronary heart disease, stroke, chronic kidney disease, and dementia. Despite a wide range of pharmacological and non-pharmacological treatments, BP control can be achieved in less than 50% of cases, therefore, the development of new methods to improve the effectiveness of arterial hypertension (AH) treatment is urgent. One possible approach is monitoring antihypertensive drug (AHD) for their correspondence to the therapeutic range (TR). AIM: To analyze the effect of serum concentrations of lisinopril, indapamide and amlodipine on blood pressure parameters in patients with stage III essential hypertension taking these drugs in a triple combination. METHODS: A cross-sectional clinical study included 147 patients with stage III essential hypertension who were simultaneously receiving the three studied AHDs (lisinopril, amlodipine, indapamide); mean age (63.7±11.0) years; 44% were men; 54% of patients had uncontrolled hypertension. Using high-performance liquid chromatography with tandem mass spectrometry (Ultimate 3000 chromatograph and TSQ Fortis mass spectrometer (ThermoFisher, USA)) the concentrations of AHDs in blood serum were analyzed: steady-state concentration (C0h) and 2 hours after administration of AHDs (C2h). Using univariate and then multivariate regression analysis, the existence of a relationship between the mean level of daytime and nighttime blood pressure, pharmacokinetic parameters (C0h, C2h, achievement of TR) and general clinical criteria (age, gender, body weight, creatinine clearance) was determined. RESULTS: The proportion of patients with C0h below TR was: 8.2% for lisinopril, 27.9% for amlodipine, 69.4% for indapamide, 8.8% for simultaneous indapamide and amlodipine, and 0.7% for the three simultaneous AHDs. The proportion of patients with non-achievement of the target BP level was the following: with C0h of lisinopril within the TR (n=135) — 56.0%, with C0h of lisinopril below the TR (n=12) — 33.0%, with C0h of amlodipine within the TR (n=106) — 57.0%, with C0h of amlodipine below the TR (n=41) — 49.0%, with C0h of indapamide within the TR (n=45) — 44.0%, with C0h of indapamide below the TR (n=102) — 59.0%, with C0h of indapamide and amlodipine simultaneously below the TR (n=13) — 85.0%, with C0h of the three drugs simultaneously below the TR (n=1) — 1 out of 1. According to the results of multiple regression analysis, a significant factor influencing the level of daytime SBP was age, daytime DBP — age and non-achievement of the TR of amlodipine and indapamide C0h; of nighttime SBP — body weight, of nighttime DBP — age and non-achievement of the TR of amlodipine and indapamide C0h. CONCLUSION: A high prevalence of subtherapeutic serum concentrations of indapamide and amlodipine has been recorded. Non-achievement of the TR level of both amlodipine and indapamide is associated with higher diastolic blood pressure with no significant effect on systolic blood pressure. The problem of poor hypertension control cannot be explained solely by serum antihypertensive drug concentrations — no convincing, unambiguous correlation has been established.
- Open Access
- 30 December 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (4) , 643-654
Structural and functional biochemistry of OATP1B3: from polymorphisms to therapeutic targets
INTRODUCTION: Organic Anion Transporting Polypeptide 1B3 (OATP1B3) plays a key role in hepatic transport of endogenous compounds, xenobiotics and drugs. In recent years, new data have been presented on the molecular organization, mechanisms of function and regulation, genetic polymorphisms of OATP1B3, and its clinical significance in pharmacokinetics, diagnosis and treatment. Of particular interest is the extrahepatic expression of the transporter, which opens new prospects for targeted therapy. AIM: To identify the structural and functional biochemical features of OATP1B3 transporter, its genetic polymorphisms and their impact on pharmacokinetic and therapeutic properties, determine the potential of OATP1B3 for targeted and personalized medicine. Literature search was conducted using the following keywords: OATP1B3, SLCO1B3, transporter, substrate specificity, regulation, oncology, and hepatocellular carcinoma in Russian and English. Electronic databases providing access to peer-reviewed scientific articles were used: eLibrary, Medline/PubMed, and Google Scholar. The search was conducted between 2000 and 2004 to cover the current data, starting from the first publications on OATP1B3 identification, but also taking into account earlier key works on OATP1B3 identification. This review presents the biochemical features of OATP1B3 localization, structure, and transport cycle. It also systematizes literature data on substrates, inhibitors, and inducers of the transporter protein, describes regulatory mechanisms and identifies the clinical significance of this transporter protein. OATP1B3 is demonstrated to have tissue-specific localization: it is normally expressed in the liver, but in oncologic pathologies is detected in the cytosol of gastrointestinal and lung tumor cells, where it may participate in signaling pathways. Evidence of high genetic variability of the SLCO1B3 gene is presented. The clinical potential of OATP1B3 is confirmed by its role in diagnostics (liver MRI with gadoxetate) and the possibility of targeted delivery of chemotherapeutic drugs. CONCLUSION: OATP1B3 is an influx transporter protein that has an important clinical significance participating in transport of statins, cytostatics and diagnostic contrast agents, and its activity is modulated by post-translational modifications.
- 30 December 2025
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 33 (4) , 643-654
Open AccessStructural and functional biochemistry of OATP1B3: from polymorphisms to therapeutic targets
INTRODUCTION: Organic Anion Transporting Polypeptide 1B3 (OATP1B3) plays a key role in hepatic transport of endogenous compounds, xenobiotics and drugs. In recent years, new data have been presented on the molecular organization, mechanisms of function and regulation, genetic polymorphisms of OATP1B3, and its clinical significance in pharmacokinetics, diagnosis and treatment. Of particular interest is the extrahepatic expression of the transporter, which opens new prospects for targeted therapy. AIM: To identify the structural and functional biochemical features of OATP1B3 transporter, its genetic polymorphisms and their impact on pharmacokinetic and therapeutic properties, determine the potential of OATP1B3 for targeted and personalized medicine. Literature search was conducted using the following keywords: OATP1B3, SLCO1B3, transporter, substrate specificity, regulation, oncology, and hepatocellular carcinoma in Russian and English. Electronic databases providing access to peer-reviewed scientific articles were used: eLibrary, Medline/PubMed, and Google Scholar. The search was conducted between 2000 and 2004 to cover the current data, starting from the first publications on OATP1B3 identification, but also taking into account earlier key works on OATP1B3 identification. This review presents the biochemical features of OATP1B3 localization, structure, and transport cycle. It also systematizes literature data on substrates, inhibitors, and inducers of the transporter protein, describes regulatory mechanisms and identifies the clinical significance of this transporter protein. OATP1B3 is demonstrated to have tissue-specific localization: it is normally expressed in the liver, but in oncologic pathologies is detected in the cytosol of gastrointestinal and lung tumor cells, where it may participate in signaling pathways. Evidence of high genetic variability of the SLCO1B3 gene is presented. The clinical potential of OATP1B3 is confirmed by its role in diagnostics (liver MRI with gadoxetate) and the possibility of targeted delivery of chemotherapeutic drugs. CONCLUSION: OATP1B3 is an influx transporter protein that has an important clinical significance participating in transport of statins, cytostatics and diagnostic contrast agents, and its activity is modulated by post-translational modifications.
- 26 December 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3
Evaluation of the effect of ethylmethylhydroxypyridine succinate on the activity of the BCRP transporter protein in vitro
Relevance. Breast cancer resistance protein (BCRP) is one of the main clinically significant transporter proteins that play an important role in the pharmacokinetics of drugs. To predict the development of drug interactions at the level of this transporter, it is recommended to test drugs for belonging to substrates and BCRP inhibitors. Objective. Comparative assessment of the effect of ethylmethylhydroxypyridine succinate (EMHPS) on the activity of the BCRP transporter protein under in vitro conditions using sulfasalazine as a substrate. Materials and methods. The study was performed in vitro on Caco-2 cells that were cultured in a transwell-system. Sulfasalazine was used as a BCRP substrate. EMHPS was used in the concentration range of 0.1 — 500 µM. A classic BCRP inhibitor, quercetin, was used as a comparison drug. The concentration of sulfasalazine in the transport medium was determined by HPLC-MS/MS. Results. During the study, it was shown that EMHPS inhibited BCRP activity in the concentration range of 50–500 µM. In terms of inhibitory activity, the tested drug was inferior to the comparison drug quercetin — the IC 50 of quercetin was 0.2 µM, the IC 50 of EMHPS was 37.5 µM. To study the clinical significance of the inhibitory ability of EMHPS, the ratio C max of EMHPS/IC 50 (predicts systemic inhibition of BCRP in the liver, kidneys, and histohematic barriers) and the ratio dose of EMHPS/ 250 ml / IC 50 (predicts inhibition of BCRP in the intestine) were calculated. It has been shown that EMHPS can clinically significantly inhibit BCRP in the intestine. Conclusion. Thus, EMHPS is an inhibitor of BCRP in vitro . To confirm the significance of the obtained results for the development of drug-drug interactions, it is necessary to conduct clinical studies.
- 26 December 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3
Evaluation of the effect of ethylmethylhydroxypyridine succinate on the activity of the BCRP transporter protein in vitro
Relevance. Breast cancer resistance protein (BCRP) is one of the main clinically significant transporter proteins that play an important role in the pharmacokinetics of drugs. To predict the development of drug interactions at the level of this transporter, it is recommended to test drugs for belonging to substrates and BCRP inhibitors. Objective. Comparative assessment of the effect of ethylmethylhydroxypyridine succinate (EMHPS) on the activity of the BCRP transporter protein under in vitro conditions using sulfasalazine as a substrate. Materials and methods. The study was performed in vitro on Caco-2 cells that were cultured in a transwell-system. Sulfasalazine was used as a BCRP substrate. EMHPS was used in the concentration range of 0.1 — 500 µM. A classic BCRP inhibitor, quercetin, was used as a comparison drug. The concentration of sulfasalazine in the transport medium was determined by HPLC-MS/MS. Results. During the study, it was shown that EMHPS inhibited BCRP activity in the concentration range of 50–500 µM. In terms of inhibitory activity, the tested drug was inferior to the comparison drug quercetin — the IC 50 of quercetin was 0.2 µM, the IC 50 of EMHPS was 37.5 µM. To study the clinical significance of the inhibitory ability of EMHPS, the ratio C max of EMHPS/IC 50 (predicts systemic inhibition of BCRP in the liver, kidneys, and histohematic barriers) and the ratio dose of EMHPS/ 250 ml / IC 50 (predicts inhibition of BCRP in the intestine) were calculated. It has been shown that EMHPS can clinically significantly inhibit BCRP in the intestine. Conclusion. Thus, EMHPS is an inhibitor of BCRP in vitro . To confirm the significance of the obtained results for the development of drug-drug interactions, it is necessary to conduct clinical studies.
- Open Access
- 23 August 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 27-35
Pharmacokinetics of metoprolol tartrate in patients with and without controlled arterial hypertension
Background. Metoprolol is a selective beta-blocker that is most commonly used in the pharmacotherapy of cardiovascular diseases, including hypertension (AH).Objective. To evaluate the pharmacokinetics of metoprolol tartrate in patients with controlled and uncontrolled AH.Materials and methods. An open cohort study was conducted at the Hospital Therapy Department of the Ryazan State Medical University in the Ryazan Regional Clinical Cardiology Dispensary. The study included 45 patients, including 29 with uncontrolled AH and 15 with controlled AH. All patients regularly take any two antihypertensive drugs (AHD) (lisinopril, amlodipine, and metoprolol tartrate) along with indapamide for a month. In the morning before and 2 h after taking metoprolol, venous blood samples were collected to assess the concentration of the analyzed substance (C0h and C2h, respectively) using high-performance liquid chromatography with tandem mass spectrometry.Results. Analysis of C0h and C2h of metoprolol tartrate did not show statistically significant differences in patients with controlled and uncontrolled AH. In 93 % of patients, C0h and in 57.8 %, C2h were below the lower limit of the therapeutic range, without statistically significant differences in controlled and uncontrolled AH. The median daily dose of metoprolol tartrate was 50 (25; 75) mg, which is insufficient according to the AH guidelines (the recommended dose is 100 mg).Conclusion. Thus, the pharmacokinetics of metoprolol tartrate did not make a significant contribution to achieving blood pressure control. In most cases, metoprolol tartrate concentration is below the therapeutic range, which is associated with a low drug dose.
- 23 August 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 27-35
Open AccessPharmacokinetics of metoprolol tartrate in patients with and without controlled arterial hypertension
Background. Metoprolol is a selective beta-blocker that is most commonly used in the pharmacotherapy of cardiovascular diseases, including hypertension (AH).Objective. To evaluate the pharmacokinetics of metoprolol tartrate in patients with controlled and uncontrolled AH.Materials and methods. An open cohort study was conducted at the Hospital Therapy Department of the Ryazan State Medical University in the Ryazan Regional Clinical Cardiology Dispensary. The study included 45 patients, including 29 with uncontrolled AH and 15 with controlled AH. All patients regularly take any two antihypertensive drugs (AHD) (lisinopril, amlodipine, and metoprolol tartrate) along with indapamide for a month. In the morning before and 2 h after taking metoprolol, venous blood samples were collected to assess the concentration of the analyzed substance (C0h and C2h, respectively) using high-performance liquid chromatography with tandem mass spectrometry.Results. Analysis of C0h and C2h of metoprolol tartrate did not show statistically significant differences in patients with controlled and uncontrolled AH. In 93 % of patients, C0h and in 57.8 %, C2h were below the lower limit of the therapeutic range, without statistically significant differences in controlled and uncontrolled AH. The median daily dose of metoprolol tartrate was 50 (25; 75) mg, which is insufficient according to the AH guidelines (the recommended dose is 100 mg).Conclusion. Thus, the pharmacokinetics of metoprolol tartrate did not make a significant contribution to achieving blood pressure control. In most cases, metoprolol tartrate concentration is below the therapeutic range, which is associated with a low drug dose.
- Open Access
- 23 May 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 69-75
Valsartan pharmacokinetics in patients with controlled and uncontrolled arterial hypertension
Relevance. Arterial hypertension (AH) is widespread throughout the world. Unfortunately, only a small proportion of patients achieve target blood pressure (BP). One of the possible reasons for the ineffectiveness of AH treatment is the pharmacokinetics of antihypertensive drugs.Objective. To test valsartan pharmacokinetics in patients with AH.Material and methods. An open cohort study was conducted. The analysis included 28 patients, including 15 (53.6 %) with uncontrolled AH. All patients regularly took valsartan, amlodipine, indapamide for a month. In the morning before and 2 hours after taking valsartan, venous blood samples were taken from all patients to assess its concentration using high-performance liquid chromatography with tandem mass spectrometry.Results. Patients of the two groups were comparable in terms of major comorbidities. C0h and C2h of valsartan did not statistically differ in patients with controlled and uncontrolled AH. In 39.3 % of patients, C0h and C2h of valsartan were within the therapeutic range (TD). In 50 % of patients, C0h did not reach the lower limit of TD, and in three patients, the concentration of valsartan exceeded the upper limit of TD, in one of them it exceeded the upper limit of TD almost three times. In 13 patients for whom valsartan was not recommended, it was found in trace amounts.Conclusion. Thus, to improve the efficacy and safety of valsartan therapy, it is advisable to monitor its concentration in the blood serum.
- 23 May 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 69-75
Open AccessValsartan pharmacokinetics in patients with controlled and uncontrolled arterial hypertension
Relevance. Arterial hypertension (AH) is widespread throughout the world. Unfortunately, only a small proportion of patients achieve target blood pressure (BP). One of the possible reasons for the ineffectiveness of AH treatment is the pharmacokinetics of antihypertensive drugs.Objective. To test valsartan pharmacokinetics in patients with AH.Material and methods. An open cohort study was conducted. The analysis included 28 patients, including 15 (53.6 %) with uncontrolled AH. All patients regularly took valsartan, amlodipine, indapamide for a month. In the morning before and 2 hours after taking valsartan, venous blood samples were taken from all patients to assess its concentration using high-performance liquid chromatography with tandem mass spectrometry.Results. Patients of the two groups were comparable in terms of major comorbidities. C0h and C2h of valsartan did not statistically differ in patients with controlled and uncontrolled AH. In 39.3 % of patients, C0h and C2h of valsartan were within the therapeutic range (TD). In 50 % of patients, C0h did not reach the lower limit of TD, and in three patients, the concentration of valsartan exceeded the upper limit of TD, in one of them it exceeded the upper limit of TD almost three times. In 13 patients for whom valsartan was not recommended, it was found in trace amounts.Conclusion. Thus, to improve the efficacy and safety of valsartan therapy, it is advisable to monitor its concentration in the blood serum.